Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

Rhea-AI Summary

Palvella Therapeutics (NASDAQ:PVLA), a clinical-stage biopharmaceutical company developing therapies for rare genetic skin diseases, announced its participation in the Canaccord Genuity 45th Annual Growth Conference. The company's Founder and CEO, Wes Kaupinen, will engage in a fireside chat on August 12, 2025, at 1:00 p.m. ET.

The presentation will be accessible via live webcast on Palvella's website, with a replay available for approximately 90 days after the event. The company focuses on developing treatments for conditions that currently lack FDA-approved therapies.

News Market Reaction – PVLA

+0.86%

1 alert

+0.86% News Effect

+$4M Valuation Impact

$432M Market Cap

1.3x Rel. Volume

On the day this news was published, PVLA gained 0.86%, reflecting a mild positive market reaction. This price movement added approximately $4M to the company's valuation, bringing the market cap to $432M at that time.

Data tracked by StockTitan Argus on the day of publication.

WAYNE, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, at 1:00 p.m. ET.

A live webcast of the fireside chat will be available on the Events and Presentations section of Palvella's website at www.palvellatx.com. An archived replay of the webcast will be available for approximately 90 days following the presentation.

About Palvella Therapeutics
Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being evaluated in the Phase 3 SELVA clinical trial in microcystic lymphatic malformations and the Phase 2 TOIVA clinical trial in cutaneous venous malformations. For more information, please visit www.palvellatx.com or follow Palvella on LinkedIn or X (formerly known as Twitter). QTORIN™ rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency for any indication.

Contact Information

Investors
Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
wes.kaupinen@palvellatx.com

Media
Marcy Nanus
Managing Partner, Trilon Advisors, LLC
mnanus@trilonadvisors.com

FAQ

When is Palvella Therapeutics (PVLA) presenting at the Canaccord Genuity Conference?

Palvella Therapeutics will present at the conference on Tuesday, August 12, 2025, at 1:00 p.m. ET through a fireside chat format.

How can investors access Palvella Therapeutics' (PVLA) Canaccord conference presentation?

Investors can access the presentation through a live webcast on Palvella's website (www.palvellatx.com) in the Events and Presentations section. A replay will be available for approximately 90 days.

Who will be presenting for Palvella Therapeutics (PVLA) at the Canaccord conference?

Wes Kaupinen, the Founder and Chief Executive Officer of Palvella Therapeutics, will lead the fireside chat presentation.

What is Palvella Therapeutics' (PVLA) main business focus?

Palvella is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare genetic skin diseases that currently have no FDA-approved treatments.